Global Hepatitis B Vaccines Market Growth 2026-2032
The global Hepatitis B Vaccines market size is predicted to grow from US$ 1424 million in 2025 to US$ 2268 million in 2032; it is expected to grow at a CAGR of 6.7% from 2026 to 2032.
Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.In 2025, global Hepatitis B vaccine production reached approximately 391 million doses and price si about 3.72 USD/dose.The average gross profit margin of this product is 70%.
The fundamental drivers of the HepB vaccine market are the certainty of national immunization programs and long-term public-health goals tied to reducing HBV-related burden. Routine infant and pediatric vaccination provides a stable demand base in many regions, while increasingly risk-stratified adult prevention makes demand more visible across occupational exposure groups, people with chronic conditions or immunocompromise, and settings shaped by mobility and cross-border travel. In parallel, the market is evolving from single-product supply toward combination and service-enabled ecosystems, where supply stability, release capacity, cold-chain reach, and channel depth become durable competitive advantages.
As a highly regulated biologic, HepB vaccines face challenges centered on quality consistency and supply reliability. From antigen expression and purification to adjuvant compatibility and fill-finish, small process variations can escalate into batch-release and reputational risks. Public trust is also critical: safety communication, pharmacovigilance, and adverse-event management must be systematic and credible. Structurally, mature program markets may intensify price- and tender-driven commoditization, while adult and international markets depend on indication strategy, vaccination adherence, and affordability to convert potential demand into realized uptake.
Downstream demand is shifting from “coverage-driven” to “population precision and life-course management.” Pediatric pathways increasingly integrate with perinatal and maternal–child health workflows, while adult pathways emphasize high-risk identification, occupational-health linkage, and standardized post-exposure prevention routines. Another notable trend is the structural impact of combination vaccines and convenience: simpler schedules and more digital follow-up can materially improve catch-up and adult access. At the same time, mobility and global health collaboration raise expectations for stable supply, traceability systems, and multi-jurisdiction compliance readiness.
Upstream value concentrates on the biomanufacturing inputs required for recombinant antigen production and sterile drug-product processing: cell banks/strains and media systems, fermentation or cell-culture consumables, purification materials such as chromatography resins and ultrafiltration membranes, and formulation components including adjuvants, buffers, and stabilizers. In fill-finish and packaging, consistency requirements extend to vials or prefilled syringes, stoppers and seals, labeling and serialization/traceability, and cold-chain packaging materials. Overall, the grade, continuity, and change-control discipline of upstream supplies directly shape batch-to-batch consistency, release efficiency, and predictable scale delivery.
LP Information, Inc. (LPI) ' newest research report, the “Hepatitis B Vaccines Industry Forecast” looks at past sales and reviews total world Hepatitis B Vaccines sales in 2025, providing a comprehensive analysis by region and market sector of projected Hepatitis B Vaccines sales for 2026 through 2032. With Hepatitis B Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hepatitis B Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Hepatitis B Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hepatitis B Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hepatitis B Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatitis B Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatitis B Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of Hepatitis B Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Hepatitis B Vaccines market?
What factors are driving Hepatitis B Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hepatitis B Vaccines market opportunities vary by end market size?
How does Hepatitis B Vaccines break out by Type, by Application?
Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.In 2025, global Hepatitis B vaccine production reached approximately 391 million doses and price si about 3.72 USD/dose.The average gross profit margin of this product is 70%.
The fundamental drivers of the HepB vaccine market are the certainty of national immunization programs and long-term public-health goals tied to reducing HBV-related burden. Routine infant and pediatric vaccination provides a stable demand base in many regions, while increasingly risk-stratified adult prevention makes demand more visible across occupational exposure groups, people with chronic conditions or immunocompromise, and settings shaped by mobility and cross-border travel. In parallel, the market is evolving from single-product supply toward combination and service-enabled ecosystems, where supply stability, release capacity, cold-chain reach, and channel depth become durable competitive advantages.
As a highly regulated biologic, HepB vaccines face challenges centered on quality consistency and supply reliability. From antigen expression and purification to adjuvant compatibility and fill-finish, small process variations can escalate into batch-release and reputational risks. Public trust is also critical: safety communication, pharmacovigilance, and adverse-event management must be systematic and credible. Structurally, mature program markets may intensify price- and tender-driven commoditization, while adult and international markets depend on indication strategy, vaccination adherence, and affordability to convert potential demand into realized uptake.
Downstream demand is shifting from “coverage-driven” to “population precision and life-course management.” Pediatric pathways increasingly integrate with perinatal and maternal–child health workflows, while adult pathways emphasize high-risk identification, occupational-health linkage, and standardized post-exposure prevention routines. Another notable trend is the structural impact of combination vaccines and convenience: simpler schedules and more digital follow-up can materially improve catch-up and adult access. At the same time, mobility and global health collaboration raise expectations for stable supply, traceability systems, and multi-jurisdiction compliance readiness.
Upstream value concentrates on the biomanufacturing inputs required for recombinant antigen production and sterile drug-product processing: cell banks/strains and media systems, fermentation or cell-culture consumables, purification materials such as chromatography resins and ultrafiltration membranes, and formulation components including adjuvants, buffers, and stabilizers. In fill-finish and packaging, consistency requirements extend to vials or prefilled syringes, stoppers and seals, labeling and serialization/traceability, and cold-chain packaging materials. Overall, the grade, continuity, and change-control discipline of upstream supplies directly shape batch-to-batch consistency, release efficiency, and predictable scale delivery.
LP Information, Inc. (LPI) ' newest research report, the “Hepatitis B Vaccines Industry Forecast” looks at past sales and reviews total world Hepatitis B Vaccines sales in 2025, providing a comprehensive analysis by region and market sector of projected Hepatitis B Vaccines sales for 2026 through 2032. With Hepatitis B Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hepatitis B Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Hepatitis B Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hepatitis B Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hepatitis B Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatitis B Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatitis B Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of Hepatitis B Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Yeast Derived
- CHO Derived
- Vial Presentation
- Prefilled Syringe
- Aluminum Salt Adjuvant
- No Adjuvant
- Other
- Children
- Adult
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GSK
- NCPC
- Merck
- Bio Kangtai
- Dynavax
- AIM Vaccine
- KM Biologics
- LG Life Sciences
- Serum Institute
What is the 10-year outlook for the global Hepatitis B Vaccines market?
What factors are driving Hepatitis B Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hepatitis B Vaccines market opportunities vary by end market size?
How does Hepatitis B Vaccines break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Hepatitis B Vaccines Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Hepatitis B Vaccines by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Hepatitis B Vaccines by Country/Region, 2021, 2025 & 2032
2.2 Hepatitis B Vaccines Segment by Type
2.2.1 Yeast Derived
2.2.2 CHO Derived
2.2.3 Hepatitis B Vaccines Sales by Type
2.2.3.1 Global Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
2.2.3.2 Global Hepatitis B Vaccines Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Hepatitis B Vaccines Sale Price by Type (2021-2026)
2.3 Hepatitis B Vaccines Segment by Form Factor & Presentation
2.3.1 Vial Presentation
2.3.2 Prefilled Syringe
2.3.3 Hepatitis B Vaccines Sales by Form Factor & Presentation
2.3.3.1 Global Hepatitis B Vaccines Sales Market Share by Form Factor & Presentation (2021-2026)
2.3.3.2 Global Hepatitis B Vaccines Revenue and Market Share by Form Factor & Presentation (2021-2026)
2.3.3.3 Global Hepatitis B Vaccines Sale Price by Form Factor & Presentation (2021-2026)
2.4 Hepatitis B Vaccines Segment by Adjuvant System
2.4.1 Aluminum Salt Adjuvant
2.4.2 No Adjuvant
2.4.3 Other
2.4.4 Hepatitis B Vaccines Sales by Adjuvant System
2.4.4.1 Global Hepatitis B Vaccines Sales Market Share by Adjuvant System (2021-2026)
2.4.4.2 Global Hepatitis B Vaccines Revenue and Market Share by Adjuvant System (2021-2026)
2.4.4.3 Global Hepatitis B Vaccines Sale Price by Adjuvant System (2021-2026)
2.5 Hepatitis B Vaccines Segment by Application
2.5.1 Children
2.5.2 Adult
2.5.3 Hepatitis B Vaccines Sales by Application
2.5.3.1 Global Hepatitis B Vaccines Sale Market Share by Application (2021-2026)
2.5.3.2 Global Hepatitis B Vaccines Revenue and Market Share by Application (2021-2026)
2.5.3.3 Global Hepatitis B Vaccines Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Hepatitis B Vaccines Breakdown Data by Company
3.1.1 Global Hepatitis B Vaccines Annual Sales by Company (2021-2026)
3.1.2 Global Hepatitis B Vaccines Sales Market Share by Company (2021-2026)
3.2 Global Hepatitis B Vaccines Annual Revenue by Company (2021-2026)
3.2.1 Global Hepatitis B Vaccines Revenue by Company (2021-2026)
3.2.2 Global Hepatitis B Vaccines Revenue Market Share by Company (2021-2026)
3.3 Global Hepatitis B Vaccines Sale Price by Company
3.4 Key Manufacturers Hepatitis B Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hepatitis B Vaccines Product Location Distribution
3.4.2 Players Hepatitis B Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HEPATITIS B VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Hepatitis B Vaccines Market Size by Geographic Region (2021-2026)
4.1.1 Global Hepatitis B Vaccines Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Hepatitis B Vaccines Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Hepatitis B Vaccines Market Size by Country/Region (2021-2026)
4.2.1 Global Hepatitis B Vaccines Annual Sales by Country/Region (2021-2026)
4.2.2 Global Hepatitis B Vaccines Annual Revenue by Country/Region (2021-2026)
4.3 Americas Hepatitis B Vaccines Sales Growth
4.4 APAC Hepatitis B Vaccines Sales Growth
4.5 Europe Hepatitis B Vaccines Sales Growth
4.6 Middle East & Africa Hepatitis B Vaccines Sales Growth
5 AMERICAS
5.1 Americas Hepatitis B Vaccines Sales by Country
5.1.1 Americas Hepatitis B Vaccines Sales by Country (2021-2026)
5.1.2 Americas Hepatitis B Vaccines Revenue by Country (2021-2026)
5.2 Americas Hepatitis B Vaccines Sales by Type (2021-2026)
5.3 Americas Hepatitis B Vaccines Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hepatitis B Vaccines Sales by Region
6.1.1 APAC Hepatitis B Vaccines Sales by Region (2021-2026)
6.1.2 APAC Hepatitis B Vaccines Revenue by Region (2021-2026)
6.2 APAC Hepatitis B Vaccines Sales by Type (2021-2026)
6.3 APAC Hepatitis B Vaccines Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Hepatitis B Vaccines by Country
7.1.1 Europe Hepatitis B Vaccines Sales by Country (2021-2026)
7.1.2 Europe Hepatitis B Vaccines Revenue by Country (2021-2026)
7.2 Europe Hepatitis B Vaccines Sales by Type (2021-2026)
7.3 Europe Hepatitis B Vaccines Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Hepatitis B Vaccines by Country
8.1.1 Middle East & Africa Hepatitis B Vaccines Sales by Country (2021-2026)
8.1.2 Middle East & Africa Hepatitis B Vaccines Revenue by Country (2021-2026)
8.2 Middle East & Africa Hepatitis B Vaccines Sales by Type (2021-2026)
8.3 Middle East & Africa Hepatitis B Vaccines Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hepatitis B Vaccines
10.3 Manufacturing Process Analysis of Hepatitis B Vaccines
10.4 Industry Chain Structure of Hepatitis B Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Hepatitis B Vaccines Distributors
11.3 Hepatitis B Vaccines Customer
12 WORLD FORECAST REVIEW FOR HEPATITIS B VACCINES BY GEOGRAPHIC REGION
12.1 Global Hepatitis B Vaccines Market Size Forecast by Region
12.1.1 Global Hepatitis B Vaccines Forecast by Region (2027-2032)
12.1.2 Global Hepatitis B Vaccines Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Hepatitis B Vaccines Forecast by Type (2027-2032)
12.7 Global Hepatitis B Vaccines Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Hepatitis B Vaccines Product Portfolios and Specifications
13.1.3 GSK Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 NCPC
13.2.1 NCPC Company Information
13.2.2 NCPC Hepatitis B Vaccines Product Portfolios and Specifications
13.2.3 NCPC Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 NCPC Main Business Overview
13.2.5 NCPC Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Hepatitis B Vaccines Product Portfolios and Specifications
13.3.3 Merck Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Bio Kangtai
13.4.1 Bio Kangtai Company Information
13.4.2 Bio Kangtai Hepatitis B Vaccines Product Portfolios and Specifications
13.4.3 Bio Kangtai Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Bio Kangtai Main Business Overview
13.4.5 Bio Kangtai Latest Developments
13.5 Dynavax
13.5.1 Dynavax Company Information
13.5.2 Dynavax Hepatitis B Vaccines Product Portfolios and Specifications
13.5.3 Dynavax Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Dynavax Main Business Overview
13.5.5 Dynavax Latest Developments
13.6 AIM Vaccine
13.6.1 AIM Vaccine Company Information
13.6.2 AIM Vaccine Hepatitis B Vaccines Product Portfolios and Specifications
13.6.3 AIM Vaccine Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 AIM Vaccine Main Business Overview
13.6.5 AIM Vaccine Latest Developments
13.7 KM Biologics
13.7.1 KM Biologics Company Information
13.7.2 KM Biologics Hepatitis B Vaccines Product Portfolios and Specifications
13.7.3 KM Biologics Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 KM Biologics Main Business Overview
13.7.5 KM Biologics Latest Developments
13.8 LG Life Sciences
13.8.1 LG Life Sciences Company Information
13.8.2 LG Life Sciences Hepatitis B Vaccines Product Portfolios and Specifications
13.8.3 LG Life Sciences Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 LG Life Sciences Main Business Overview
13.8.5 LG Life Sciences Latest Developments
13.9 Serum Institute
13.9.1 Serum Institute Company Information
13.9.2 Serum Institute Hepatitis B Vaccines Product Portfolios and Specifications
13.9.3 Serum Institute Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Serum Institute Main Business Overview
13.9.5 Serum Institute Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Hepatitis B Vaccines Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Hepatitis B Vaccines by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Hepatitis B Vaccines by Country/Region, 2021, 2025 & 2032
2.2 Hepatitis B Vaccines Segment by Type
2.2.1 Yeast Derived
2.2.2 CHO Derived
2.2.3 Hepatitis B Vaccines Sales by Type
2.2.3.1 Global Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
2.2.3.2 Global Hepatitis B Vaccines Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Hepatitis B Vaccines Sale Price by Type (2021-2026)
2.3 Hepatitis B Vaccines Segment by Form Factor & Presentation
2.3.1 Vial Presentation
2.3.2 Prefilled Syringe
2.3.3 Hepatitis B Vaccines Sales by Form Factor & Presentation
2.3.3.1 Global Hepatitis B Vaccines Sales Market Share by Form Factor & Presentation (2021-2026)
2.3.3.2 Global Hepatitis B Vaccines Revenue and Market Share by Form Factor & Presentation (2021-2026)
2.3.3.3 Global Hepatitis B Vaccines Sale Price by Form Factor & Presentation (2021-2026)
2.4 Hepatitis B Vaccines Segment by Adjuvant System
2.4.1 Aluminum Salt Adjuvant
2.4.2 No Adjuvant
2.4.3 Other
2.4.4 Hepatitis B Vaccines Sales by Adjuvant System
2.4.4.1 Global Hepatitis B Vaccines Sales Market Share by Adjuvant System (2021-2026)
2.4.4.2 Global Hepatitis B Vaccines Revenue and Market Share by Adjuvant System (2021-2026)
2.4.4.3 Global Hepatitis B Vaccines Sale Price by Adjuvant System (2021-2026)
2.5 Hepatitis B Vaccines Segment by Application
2.5.1 Children
2.5.2 Adult
2.5.3 Hepatitis B Vaccines Sales by Application
2.5.3.1 Global Hepatitis B Vaccines Sale Market Share by Application (2021-2026)
2.5.3.2 Global Hepatitis B Vaccines Revenue and Market Share by Application (2021-2026)
2.5.3.3 Global Hepatitis B Vaccines Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Hepatitis B Vaccines Breakdown Data by Company
3.1.1 Global Hepatitis B Vaccines Annual Sales by Company (2021-2026)
3.1.2 Global Hepatitis B Vaccines Sales Market Share by Company (2021-2026)
3.2 Global Hepatitis B Vaccines Annual Revenue by Company (2021-2026)
3.2.1 Global Hepatitis B Vaccines Revenue by Company (2021-2026)
3.2.2 Global Hepatitis B Vaccines Revenue Market Share by Company (2021-2026)
3.3 Global Hepatitis B Vaccines Sale Price by Company
3.4 Key Manufacturers Hepatitis B Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hepatitis B Vaccines Product Location Distribution
3.4.2 Players Hepatitis B Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HEPATITIS B VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Hepatitis B Vaccines Market Size by Geographic Region (2021-2026)
4.1.1 Global Hepatitis B Vaccines Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Hepatitis B Vaccines Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Hepatitis B Vaccines Market Size by Country/Region (2021-2026)
4.2.1 Global Hepatitis B Vaccines Annual Sales by Country/Region (2021-2026)
4.2.2 Global Hepatitis B Vaccines Annual Revenue by Country/Region (2021-2026)
4.3 Americas Hepatitis B Vaccines Sales Growth
4.4 APAC Hepatitis B Vaccines Sales Growth
4.5 Europe Hepatitis B Vaccines Sales Growth
4.6 Middle East & Africa Hepatitis B Vaccines Sales Growth
5 AMERICAS
5.1 Americas Hepatitis B Vaccines Sales by Country
5.1.1 Americas Hepatitis B Vaccines Sales by Country (2021-2026)
5.1.2 Americas Hepatitis B Vaccines Revenue by Country (2021-2026)
5.2 Americas Hepatitis B Vaccines Sales by Type (2021-2026)
5.3 Americas Hepatitis B Vaccines Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hepatitis B Vaccines Sales by Region
6.1.1 APAC Hepatitis B Vaccines Sales by Region (2021-2026)
6.1.2 APAC Hepatitis B Vaccines Revenue by Region (2021-2026)
6.2 APAC Hepatitis B Vaccines Sales by Type (2021-2026)
6.3 APAC Hepatitis B Vaccines Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Hepatitis B Vaccines by Country
7.1.1 Europe Hepatitis B Vaccines Sales by Country (2021-2026)
7.1.2 Europe Hepatitis B Vaccines Revenue by Country (2021-2026)
7.2 Europe Hepatitis B Vaccines Sales by Type (2021-2026)
7.3 Europe Hepatitis B Vaccines Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Hepatitis B Vaccines by Country
8.1.1 Middle East & Africa Hepatitis B Vaccines Sales by Country (2021-2026)
8.1.2 Middle East & Africa Hepatitis B Vaccines Revenue by Country (2021-2026)
8.2 Middle East & Africa Hepatitis B Vaccines Sales by Type (2021-2026)
8.3 Middle East & Africa Hepatitis B Vaccines Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hepatitis B Vaccines
10.3 Manufacturing Process Analysis of Hepatitis B Vaccines
10.4 Industry Chain Structure of Hepatitis B Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Hepatitis B Vaccines Distributors
11.3 Hepatitis B Vaccines Customer
12 WORLD FORECAST REVIEW FOR HEPATITIS B VACCINES BY GEOGRAPHIC REGION
12.1 Global Hepatitis B Vaccines Market Size Forecast by Region
12.1.1 Global Hepatitis B Vaccines Forecast by Region (2027-2032)
12.1.2 Global Hepatitis B Vaccines Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Hepatitis B Vaccines Forecast by Type (2027-2032)
12.7 Global Hepatitis B Vaccines Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Hepatitis B Vaccines Product Portfolios and Specifications
13.1.3 GSK Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 NCPC
13.2.1 NCPC Company Information
13.2.2 NCPC Hepatitis B Vaccines Product Portfolios and Specifications
13.2.3 NCPC Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 NCPC Main Business Overview
13.2.5 NCPC Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Hepatitis B Vaccines Product Portfolios and Specifications
13.3.3 Merck Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Bio Kangtai
13.4.1 Bio Kangtai Company Information
13.4.2 Bio Kangtai Hepatitis B Vaccines Product Portfolios and Specifications
13.4.3 Bio Kangtai Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Bio Kangtai Main Business Overview
13.4.5 Bio Kangtai Latest Developments
13.5 Dynavax
13.5.1 Dynavax Company Information
13.5.2 Dynavax Hepatitis B Vaccines Product Portfolios and Specifications
13.5.3 Dynavax Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Dynavax Main Business Overview
13.5.5 Dynavax Latest Developments
13.6 AIM Vaccine
13.6.1 AIM Vaccine Company Information
13.6.2 AIM Vaccine Hepatitis B Vaccines Product Portfolios and Specifications
13.6.3 AIM Vaccine Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 AIM Vaccine Main Business Overview
13.6.5 AIM Vaccine Latest Developments
13.7 KM Biologics
13.7.1 KM Biologics Company Information
13.7.2 KM Biologics Hepatitis B Vaccines Product Portfolios and Specifications
13.7.3 KM Biologics Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 KM Biologics Main Business Overview
13.7.5 KM Biologics Latest Developments
13.8 LG Life Sciences
13.8.1 LG Life Sciences Company Information
13.8.2 LG Life Sciences Hepatitis B Vaccines Product Portfolios and Specifications
13.8.3 LG Life Sciences Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 LG Life Sciences Main Business Overview
13.8.5 LG Life Sciences Latest Developments
13.9 Serum Institute
13.9.1 Serum Institute Company Information
13.9.2 Serum Institute Hepatitis B Vaccines Product Portfolios and Specifications
13.9.3 Serum Institute Hepatitis B Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Serum Institute Main Business Overview
13.9.5 Serum Institute Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Hepatitis B Vaccines Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Hepatitis B Vaccines Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Yeast Derived
Table 4. Major Players of CHO Derived
Table 5. Global Hepatitis B Vaccines Sales by Type (2021-2026) & (M Doses)
Table 6. Global Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
Table 7. Global Hepatitis B Vaccines Revenue by Type (2021-2026) & ($ million)
Table 8. Global Hepatitis B Vaccines Revenue Market Share by Type (2021-2026)
Table 9. Global Hepatitis B Vaccines Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of Vial Presentation
Table 11. Major Players of Prefilled Syringe
Table 12. Global Hepatitis B Vaccines Sales by Form Factor & Presentation (2021-2026) & (M Doses)
Table 13. Global Hepatitis B Vaccines Sales Market Share by Form Factor & Presentation (2021-2026)
Table 14. Global Hepatitis B Vaccines Revenue by Form Factor & Presentation (2021-2026) & ($ million)
Table 15. Global Hepatitis B Vaccines Revenue Market Share by Form Factor & Presentation (2021-2026)
Table 16. Global Hepatitis B Vaccines Sale Price by Form Factor & Presentation (2021-2026) & (US$/Dose)
Table 17. Major Players of Aluminum Salt Adjuvant
Table 18. Major Players of No Adjuvant
Table 19. Major Players of Other
Table 20. Global Hepatitis B Vaccines Sales by Adjuvant System (2021-2026) & (M Doses)
Table 21. Global Hepatitis B Vaccines Sales Market Share by Adjuvant System (2021-2026)
Table 22. Global Hepatitis B Vaccines Revenue by Adjuvant System (2021-2026) & ($ million)
Table 23. Global Hepatitis B Vaccines Revenue Market Share by Adjuvant System (2021-2026)
Table 24. Global Hepatitis B Vaccines Sale Price by Adjuvant System (2021-2026) & (US$/Dose)
Table 25. Global Hepatitis B Vaccines Sale by Application (2021-2026) & (M Doses)
Table 26. Global Hepatitis B Vaccines Sale Market Share by Application (2021-2026)
Table 27. Global Hepatitis B Vaccines Revenue by Application (2021-2026) & ($ million)
Table 28. Global Hepatitis B Vaccines Revenue Market Share by Application (2021-2026)
Table 29. Global Hepatitis B Vaccines Sale Price by Application (2021-2026) & (US$/Dose)
Table 30. Global Hepatitis B Vaccines Sales by Company (2021-2026) & (M Doses)
Table 31. Global Hepatitis B Vaccines Sales Market Share by Company (2021-2026)
Table 32. Global Hepatitis B Vaccines Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Hepatitis B Vaccines Revenue Market Share by Company (2021-2026)
Table 34. Global Hepatitis B Vaccines Sale Price by Company (2021-2026) & (US$/Dose)
Table 35. Key Manufacturers Hepatitis B Vaccines Producing Area Distribution and Sales Area
Table 36. Players Hepatitis B Vaccines Products Offered
Table 37. Hepatitis B Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Hepatitis B Vaccines Sales by Geographic Region (2021-2026) & (M Doses)
Table 41. Global Hepatitis B Vaccines Sales Market Share Geographic Region (2021-2026)
Table 42. Global Hepatitis B Vaccines Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Hepatitis B Vaccines Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Hepatitis B Vaccines Sales by Country/Region (2021-2026) & (M Doses)
Table 45. Global Hepatitis B Vaccines Sales Market Share by Country/Region (2021-2026)
Table 46. Global Hepatitis B Vaccines Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Hepatitis B Vaccines Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Hepatitis B Vaccines Sales by Country (2021-2026) & (M Doses)
Table 49. Americas Hepatitis B Vaccines Sales Market Share by Country (2021-2026)
Table 50. Americas Hepatitis B Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Hepatitis B Vaccines Sales by Type (2021-2026) & (M Doses)
Table 52. Americas Hepatitis B Vaccines Sales by Application (2021-2026) & (M Doses)
Table 53. APAC Hepatitis B Vaccines Sales by Region (2021-2026) & (M Doses)
Table 54. APAC Hepatitis B Vaccines Sales Market Share by Region (2021-2026)
Table 55. APAC Hepatitis B Vaccines Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Hepatitis B Vaccines Sales by Type (2021-2026) & (M Doses)
Table 57. APAC Hepatitis B Vaccines Sales by Application (2021-2026) & (M Doses)
Table 58. Europe Hepatitis B Vaccines Sales by Country (2021-2026) & (M Doses)
Table 59. Europe Hepatitis B Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Hepatitis B Vaccines Sales by Type (2021-2026) & (M Doses)
Table 61. Europe Hepatitis B Vaccines Sales by Application (2021-2026) & (M Doses)
Table 62. Middle East & Africa Hepatitis B Vaccines Sales by Country (2021-2026) & (M Doses)
Table 63. Middle East & Africa Hepatitis B Vaccines Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Hepatitis B Vaccines Sales by Type (2021-2026) & (M Doses)
Table 65. Middle East & Africa Hepatitis B Vaccines Sales by Application (2021-2026) & (M Doses)
Table 66. Key Market Drivers & Growth Opportunities of Hepatitis B Vaccines
Table 67. Key Market Challenges & Risks of Hepatitis B Vaccines
Table 68. Key Industry Trends of Hepatitis B Vaccines
Table 69. Hepatitis B Vaccines Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Hepatitis B Vaccines Distributors List
Table 72. Hepatitis B Vaccines Customer List
Table 73. Global Hepatitis B Vaccines Sales Forecast by Region (2027-2032) & (M Doses)
Table 74. Global Hepatitis B Vaccines Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Hepatitis B Vaccines Sales Forecast by Country (2027-2032) & (M Doses)
Table 76. Americas Hepatitis B Vaccines Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Hepatitis B Vaccines Sales Forecast by Region (2027-2032) & (M Doses)
Table 78. APAC Hepatitis B Vaccines Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Hepatitis B Vaccines Sales Forecast by Country (2027-2032) & (M Doses)
Table 80. Europe Hepatitis B Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Hepatitis B Vaccines Sales Forecast by Country (2027-2032) & (M Doses)
Table 82. Middle East & Africa Hepatitis B Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Hepatitis B Vaccines Sales Forecast by Type (2027-2032) & (M Doses)
Table 84. Global Hepatitis B Vaccines Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Hepatitis B Vaccines Sales Forecast by Application (2027-2032) & (M Doses)
Table 86. Global Hepatitis B Vaccines Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. GSK Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 88. GSK Hepatitis B Vaccines Product Portfolios and Specifications
Table 89. GSK Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 90. GSK Main Business
Table 91. GSK Latest Developments
Table 92. NCPC Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 93. NCPC Hepatitis B Vaccines Product Portfolios and Specifications
Table 94. NCPC Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 95. NCPC Main Business
Table 96. NCPC Latest Developments
Table 97. Merck Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 98. Merck Hepatitis B Vaccines Product Portfolios and Specifications
Table 99. Merck Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 100. Merck Main Business
Table 101. Merck Latest Developments
Table 102. Bio Kangtai Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 103. Bio Kangtai Hepatitis B Vaccines Product Portfolios and Specifications
Table 104. Bio Kangtai Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Bio Kangtai Main Business
Table 106. Bio Kangtai Latest Developments
Table 107. Dynavax Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 108. Dynavax Hepatitis B Vaccines Product Portfolios and Specifications
Table 109. Dynavax Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 110. Dynavax Main Business
Table 111. Dynavax Latest Developments
Table 112. AIM Vaccine Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 113. AIM Vaccine Hepatitis B Vaccines Product Portfolios and Specifications
Table 114. AIM Vaccine Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 115. AIM Vaccine Main Business
Table 116. AIM Vaccine Latest Developments
Table 117. KM Biologics Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 118. KM Biologics Hepatitis B Vaccines Product Portfolios and Specifications
Table 119. KM Biologics Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 120. KM Biologics Main Business
Table 121. KM Biologics Latest Developments
Table 122. LG Life Sciences Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 123. LG Life Sciences Hepatitis B Vaccines Product Portfolios and Specifications
Table 124. LG Life Sciences Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 125. LG Life Sciences Main Business
Table 126. LG Life Sciences Latest Developments
Table 127. Serum Institute Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 128. Serum Institute Hepatitis B Vaccines Product Portfolios and Specifications
Table 129. Serum Institute Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 130. Serum Institute Main Business
Table 131. Serum Institute Latest Developments
Table 1. Hepatitis B Vaccines Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Hepatitis B Vaccines Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Yeast Derived
Table 4. Major Players of CHO Derived
Table 5. Global Hepatitis B Vaccines Sales by Type (2021-2026) & (M Doses)
Table 6. Global Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
Table 7. Global Hepatitis B Vaccines Revenue by Type (2021-2026) & ($ million)
Table 8. Global Hepatitis B Vaccines Revenue Market Share by Type (2021-2026)
Table 9. Global Hepatitis B Vaccines Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of Vial Presentation
Table 11. Major Players of Prefilled Syringe
Table 12. Global Hepatitis B Vaccines Sales by Form Factor & Presentation (2021-2026) & (M Doses)
Table 13. Global Hepatitis B Vaccines Sales Market Share by Form Factor & Presentation (2021-2026)
Table 14. Global Hepatitis B Vaccines Revenue by Form Factor & Presentation (2021-2026) & ($ million)
Table 15. Global Hepatitis B Vaccines Revenue Market Share by Form Factor & Presentation (2021-2026)
Table 16. Global Hepatitis B Vaccines Sale Price by Form Factor & Presentation (2021-2026) & (US$/Dose)
Table 17. Major Players of Aluminum Salt Adjuvant
Table 18. Major Players of No Adjuvant
Table 19. Major Players of Other
Table 20. Global Hepatitis B Vaccines Sales by Adjuvant System (2021-2026) & (M Doses)
Table 21. Global Hepatitis B Vaccines Sales Market Share by Adjuvant System (2021-2026)
Table 22. Global Hepatitis B Vaccines Revenue by Adjuvant System (2021-2026) & ($ million)
Table 23. Global Hepatitis B Vaccines Revenue Market Share by Adjuvant System (2021-2026)
Table 24. Global Hepatitis B Vaccines Sale Price by Adjuvant System (2021-2026) & (US$/Dose)
Table 25. Global Hepatitis B Vaccines Sale by Application (2021-2026) & (M Doses)
Table 26. Global Hepatitis B Vaccines Sale Market Share by Application (2021-2026)
Table 27. Global Hepatitis B Vaccines Revenue by Application (2021-2026) & ($ million)
Table 28. Global Hepatitis B Vaccines Revenue Market Share by Application (2021-2026)
Table 29. Global Hepatitis B Vaccines Sale Price by Application (2021-2026) & (US$/Dose)
Table 30. Global Hepatitis B Vaccines Sales by Company (2021-2026) & (M Doses)
Table 31. Global Hepatitis B Vaccines Sales Market Share by Company (2021-2026)
Table 32. Global Hepatitis B Vaccines Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Hepatitis B Vaccines Revenue Market Share by Company (2021-2026)
Table 34. Global Hepatitis B Vaccines Sale Price by Company (2021-2026) & (US$/Dose)
Table 35. Key Manufacturers Hepatitis B Vaccines Producing Area Distribution and Sales Area
Table 36. Players Hepatitis B Vaccines Products Offered
Table 37. Hepatitis B Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Hepatitis B Vaccines Sales by Geographic Region (2021-2026) & (M Doses)
Table 41. Global Hepatitis B Vaccines Sales Market Share Geographic Region (2021-2026)
Table 42. Global Hepatitis B Vaccines Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Hepatitis B Vaccines Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Hepatitis B Vaccines Sales by Country/Region (2021-2026) & (M Doses)
Table 45. Global Hepatitis B Vaccines Sales Market Share by Country/Region (2021-2026)
Table 46. Global Hepatitis B Vaccines Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Hepatitis B Vaccines Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Hepatitis B Vaccines Sales by Country (2021-2026) & (M Doses)
Table 49. Americas Hepatitis B Vaccines Sales Market Share by Country (2021-2026)
Table 50. Americas Hepatitis B Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Hepatitis B Vaccines Sales by Type (2021-2026) & (M Doses)
Table 52. Americas Hepatitis B Vaccines Sales by Application (2021-2026) & (M Doses)
Table 53. APAC Hepatitis B Vaccines Sales by Region (2021-2026) & (M Doses)
Table 54. APAC Hepatitis B Vaccines Sales Market Share by Region (2021-2026)
Table 55. APAC Hepatitis B Vaccines Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Hepatitis B Vaccines Sales by Type (2021-2026) & (M Doses)
Table 57. APAC Hepatitis B Vaccines Sales by Application (2021-2026) & (M Doses)
Table 58. Europe Hepatitis B Vaccines Sales by Country (2021-2026) & (M Doses)
Table 59. Europe Hepatitis B Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Hepatitis B Vaccines Sales by Type (2021-2026) & (M Doses)
Table 61. Europe Hepatitis B Vaccines Sales by Application (2021-2026) & (M Doses)
Table 62. Middle East & Africa Hepatitis B Vaccines Sales by Country (2021-2026) & (M Doses)
Table 63. Middle East & Africa Hepatitis B Vaccines Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Hepatitis B Vaccines Sales by Type (2021-2026) & (M Doses)
Table 65. Middle East & Africa Hepatitis B Vaccines Sales by Application (2021-2026) & (M Doses)
Table 66. Key Market Drivers & Growth Opportunities of Hepatitis B Vaccines
Table 67. Key Market Challenges & Risks of Hepatitis B Vaccines
Table 68. Key Industry Trends of Hepatitis B Vaccines
Table 69. Hepatitis B Vaccines Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Hepatitis B Vaccines Distributors List
Table 72. Hepatitis B Vaccines Customer List
Table 73. Global Hepatitis B Vaccines Sales Forecast by Region (2027-2032) & (M Doses)
Table 74. Global Hepatitis B Vaccines Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Hepatitis B Vaccines Sales Forecast by Country (2027-2032) & (M Doses)
Table 76. Americas Hepatitis B Vaccines Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Hepatitis B Vaccines Sales Forecast by Region (2027-2032) & (M Doses)
Table 78. APAC Hepatitis B Vaccines Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Hepatitis B Vaccines Sales Forecast by Country (2027-2032) & (M Doses)
Table 80. Europe Hepatitis B Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Hepatitis B Vaccines Sales Forecast by Country (2027-2032) & (M Doses)
Table 82. Middle East & Africa Hepatitis B Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Hepatitis B Vaccines Sales Forecast by Type (2027-2032) & (M Doses)
Table 84. Global Hepatitis B Vaccines Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Hepatitis B Vaccines Sales Forecast by Application (2027-2032) & (M Doses)
Table 86. Global Hepatitis B Vaccines Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. GSK Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 88. GSK Hepatitis B Vaccines Product Portfolios and Specifications
Table 89. GSK Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 90. GSK Main Business
Table 91. GSK Latest Developments
Table 92. NCPC Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 93. NCPC Hepatitis B Vaccines Product Portfolios and Specifications
Table 94. NCPC Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 95. NCPC Main Business
Table 96. NCPC Latest Developments
Table 97. Merck Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 98. Merck Hepatitis B Vaccines Product Portfolios and Specifications
Table 99. Merck Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 100. Merck Main Business
Table 101. Merck Latest Developments
Table 102. Bio Kangtai Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 103. Bio Kangtai Hepatitis B Vaccines Product Portfolios and Specifications
Table 104. Bio Kangtai Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Bio Kangtai Main Business
Table 106. Bio Kangtai Latest Developments
Table 107. Dynavax Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 108. Dynavax Hepatitis B Vaccines Product Portfolios and Specifications
Table 109. Dynavax Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 110. Dynavax Main Business
Table 111. Dynavax Latest Developments
Table 112. AIM Vaccine Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 113. AIM Vaccine Hepatitis B Vaccines Product Portfolios and Specifications
Table 114. AIM Vaccine Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 115. AIM Vaccine Main Business
Table 116. AIM Vaccine Latest Developments
Table 117. KM Biologics Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 118. KM Biologics Hepatitis B Vaccines Product Portfolios and Specifications
Table 119. KM Biologics Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 120. KM Biologics Main Business
Table 121. KM Biologics Latest Developments
Table 122. LG Life Sciences Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 123. LG Life Sciences Hepatitis B Vaccines Product Portfolios and Specifications
Table 124. LG Life Sciences Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 125. LG Life Sciences Main Business
Table 126. LG Life Sciences Latest Developments
Table 127. Serum Institute Basic Information, Hepatitis B Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 128. Serum Institute Hepatitis B Vaccines Product Portfolios and Specifications
Table 129. Serum Institute Hepatitis B Vaccines Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 130. Serum Institute Main Business
Table 131. Serum Institute Latest Developments
LIST OF FIGURES
Figure 1. Picture of Hepatitis B Vaccines
Figure 2. Hepatitis B Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Hepatitis B Vaccines Sales Growth Rate 2021-2032 (M Doses)
Figure 7. Global Hepatitis B Vaccines Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Hepatitis B Vaccines Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Hepatitis B Vaccines Sales Market Share by Country/Region (2025)
Figure 10. Hepatitis B Vaccines Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Yeast Derived
Figure 12. Product Picture of CHO Derived
Figure 13. Global Hepatitis B Vaccines Sales Market Share by Type in 2026
Figure 14. Global Hepatitis B Vaccines Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Vial Presentation
Figure 16. Product Picture of Prefilled Syringe
Figure 17. Global Hepatitis B Vaccines Sales Market Share by Form Factor & Presentation in 2026
Figure 18. Global Hepatitis B Vaccines Revenue Market Share by Form Factor & Presentation (2021-2026)
Figure 19. Product Picture of Aluminum Salt Adjuvant
Figure 20. Product Picture of No Adjuvant
Figure 21. Product Picture of Other
Figure 22. Global Hepatitis B Vaccines Sales Market Share by Adjuvant System in 2026
Figure 23. Global Hepatitis B Vaccines Revenue Market Share by Adjuvant System (2021-2026)
Figure 24. Hepatitis B Vaccines Consumed in Children
Figure 25. Global Hepatitis B Vaccines Market: Children (2021-2026) & (M Doses)
Figure 26. Hepatitis B Vaccines Consumed in Adult
Figure 27. Global Hepatitis B Vaccines Market: Adult (2021-2026) & (M Doses)
Figure 28. Global Hepatitis B Vaccines Sale Market Share by Application (2025)
Figure 29. Global Hepatitis B Vaccines Revenue Market Share by Application in 2026
Figure 30. Hepatitis B Vaccines Sales by Company in 2026 (M Doses)
Figure 31. Global Hepatitis B Vaccines Sales Market Share by Company in 2026
Figure 32. Hepatitis B Vaccines Revenue by Company in 2026 ($ millions)
Figure 33. Global Hepatitis B Vaccines Revenue Market Share by Company in 2026
Figure 34. Global Hepatitis B Vaccines Sales Market Share by Geographic Region (2021-2026)
Figure 35. Global Hepatitis B Vaccines Revenue Market Share by Geographic Region in 2026
Figure 36. Americas Hepatitis B Vaccines Sales 2021-2026 (M Doses)
Figure 37. Americas Hepatitis B Vaccines Revenue 2021-2026 ($ millions)
Figure 38. APAC Hepatitis B Vaccines Sales 2021-2026 (M Doses)
Figure 39. APAC Hepatitis B Vaccines Revenue 2021-2026 ($ millions)
Figure 40. Europe Hepatitis B Vaccines Sales 2021-2026 (M Doses)
Figure 41. Europe Hepatitis B Vaccines Revenue 2021-2026 ($ millions)
Figure 42. Middle East & Africa Hepatitis B Vaccines Sales 2021-2026 (M Doses)
Figure 43. Middle East & Africa Hepatitis B Vaccines Revenue 2021-2026 ($ millions)
Figure 44. Americas Hepatitis B Vaccines Sales Market Share by Country in 2026
Figure 45. Americas Hepatitis B Vaccines Revenue Market Share by Country (2021-2026)
Figure 46. Americas Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
Figure 47. Americas Hepatitis B Vaccines Sales Market Share by Application (2021-2026)
Figure 48. United States Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 49. Canada Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 50. Mexico Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 51. Brazil Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 52. APAC Hepatitis B Vaccines Sales Market Share by Region in 2026
Figure 53. APAC Hepatitis B Vaccines Revenue Market Share by Region (2021-2026)
Figure 54. APAC Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
Figure 55. APAC Hepatitis B Vaccines Sales Market Share by Application (2021-2026)
Figure 56. China Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 57. Japan Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 58. South Korea Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 59. Southeast Asia Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 60. India Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 61. Australia Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 62. China Taiwan Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 63. Europe Hepatitis B Vaccines Sales Market Share by Country in 2026
Figure 64. Europe Hepatitis B Vaccines Revenue Market Share by Country (2021-2026)
Figure 65. Europe Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
Figure 66. Europe Hepatitis B Vaccines Sales Market Share by Application (2021-2026)
Figure 67. Germany Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 68. France Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 69. UK Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 70. Italy Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 71. Russia Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 72. Middle East & Africa Hepatitis B Vaccines Sales Market Share by Country (2021-2026)
Figure 73. Middle East & Africa Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
Figure 74. Middle East & Africa Hepatitis B Vaccines Sales Market Share by Application (2021-2026)
Figure 75. Egypt Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 76. South Africa Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 77. Israel Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 78. Turkey Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 79. GCC Countries Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 80. Manufacturing Cost Structure Analysis of Hepatitis B Vaccines in 2026
Figure 81. Manufacturing Process Analysis of Hepatitis B Vaccines
Figure 82. Industry Chain Structure of Hepatitis B Vaccines
Figure 83. Channels of Distribution
Figure 84. Global Hepatitis B Vaccines Sales Market Forecast by Region (2027-2032)
Figure 85. Global Hepatitis B Vaccines Revenue Market Share Forecast by Region (2027-2032)
Figure 86. Global Hepatitis B Vaccines Sales Market Share Forecast by Type (2027-2032)
Figure 87. Global Hepatitis B Vaccines Revenue Market Share Forecast by Type (2027-2032)
Figure 88. Global Hepatitis B Vaccines Sales Market Share Forecast by Application (2027-2032)
Figure 89. Global Hepatitis B Vaccines Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Hepatitis B Vaccines
Figure 2. Hepatitis B Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Hepatitis B Vaccines Sales Growth Rate 2021-2032 (M Doses)
Figure 7. Global Hepatitis B Vaccines Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Hepatitis B Vaccines Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Hepatitis B Vaccines Sales Market Share by Country/Region (2025)
Figure 10. Hepatitis B Vaccines Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Yeast Derived
Figure 12. Product Picture of CHO Derived
Figure 13. Global Hepatitis B Vaccines Sales Market Share by Type in 2026
Figure 14. Global Hepatitis B Vaccines Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Vial Presentation
Figure 16. Product Picture of Prefilled Syringe
Figure 17. Global Hepatitis B Vaccines Sales Market Share by Form Factor & Presentation in 2026
Figure 18. Global Hepatitis B Vaccines Revenue Market Share by Form Factor & Presentation (2021-2026)
Figure 19. Product Picture of Aluminum Salt Adjuvant
Figure 20. Product Picture of No Adjuvant
Figure 21. Product Picture of Other
Figure 22. Global Hepatitis B Vaccines Sales Market Share by Adjuvant System in 2026
Figure 23. Global Hepatitis B Vaccines Revenue Market Share by Adjuvant System (2021-2026)
Figure 24. Hepatitis B Vaccines Consumed in Children
Figure 25. Global Hepatitis B Vaccines Market: Children (2021-2026) & (M Doses)
Figure 26. Hepatitis B Vaccines Consumed in Adult
Figure 27. Global Hepatitis B Vaccines Market: Adult (2021-2026) & (M Doses)
Figure 28. Global Hepatitis B Vaccines Sale Market Share by Application (2025)
Figure 29. Global Hepatitis B Vaccines Revenue Market Share by Application in 2026
Figure 30. Hepatitis B Vaccines Sales by Company in 2026 (M Doses)
Figure 31. Global Hepatitis B Vaccines Sales Market Share by Company in 2026
Figure 32. Hepatitis B Vaccines Revenue by Company in 2026 ($ millions)
Figure 33. Global Hepatitis B Vaccines Revenue Market Share by Company in 2026
Figure 34. Global Hepatitis B Vaccines Sales Market Share by Geographic Region (2021-2026)
Figure 35. Global Hepatitis B Vaccines Revenue Market Share by Geographic Region in 2026
Figure 36. Americas Hepatitis B Vaccines Sales 2021-2026 (M Doses)
Figure 37. Americas Hepatitis B Vaccines Revenue 2021-2026 ($ millions)
Figure 38. APAC Hepatitis B Vaccines Sales 2021-2026 (M Doses)
Figure 39. APAC Hepatitis B Vaccines Revenue 2021-2026 ($ millions)
Figure 40. Europe Hepatitis B Vaccines Sales 2021-2026 (M Doses)
Figure 41. Europe Hepatitis B Vaccines Revenue 2021-2026 ($ millions)
Figure 42. Middle East & Africa Hepatitis B Vaccines Sales 2021-2026 (M Doses)
Figure 43. Middle East & Africa Hepatitis B Vaccines Revenue 2021-2026 ($ millions)
Figure 44. Americas Hepatitis B Vaccines Sales Market Share by Country in 2026
Figure 45. Americas Hepatitis B Vaccines Revenue Market Share by Country (2021-2026)
Figure 46. Americas Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
Figure 47. Americas Hepatitis B Vaccines Sales Market Share by Application (2021-2026)
Figure 48. United States Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 49. Canada Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 50. Mexico Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 51. Brazil Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 52. APAC Hepatitis B Vaccines Sales Market Share by Region in 2026
Figure 53. APAC Hepatitis B Vaccines Revenue Market Share by Region (2021-2026)
Figure 54. APAC Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
Figure 55. APAC Hepatitis B Vaccines Sales Market Share by Application (2021-2026)
Figure 56. China Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 57. Japan Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 58. South Korea Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 59. Southeast Asia Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 60. India Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 61. Australia Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 62. China Taiwan Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 63. Europe Hepatitis B Vaccines Sales Market Share by Country in 2026
Figure 64. Europe Hepatitis B Vaccines Revenue Market Share by Country (2021-2026)
Figure 65. Europe Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
Figure 66. Europe Hepatitis B Vaccines Sales Market Share by Application (2021-2026)
Figure 67. Germany Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 68. France Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 69. UK Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 70. Italy Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 71. Russia Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 72. Middle East & Africa Hepatitis B Vaccines Sales Market Share by Country (2021-2026)
Figure 73. Middle East & Africa Hepatitis B Vaccines Sales Market Share by Type (2021-2026)
Figure 74. Middle East & Africa Hepatitis B Vaccines Sales Market Share by Application (2021-2026)
Figure 75. Egypt Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 76. South Africa Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 77. Israel Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 78. Turkey Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 79. GCC Countries Hepatitis B Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 80. Manufacturing Cost Structure Analysis of Hepatitis B Vaccines in 2026
Figure 81. Manufacturing Process Analysis of Hepatitis B Vaccines
Figure 82. Industry Chain Structure of Hepatitis B Vaccines
Figure 83. Channels of Distribution
Figure 84. Global Hepatitis B Vaccines Sales Market Forecast by Region (2027-2032)
Figure 85. Global Hepatitis B Vaccines Revenue Market Share Forecast by Region (2027-2032)
Figure 86. Global Hepatitis B Vaccines Sales Market Share Forecast by Type (2027-2032)
Figure 87. Global Hepatitis B Vaccines Revenue Market Share Forecast by Type (2027-2032)
Figure 88. Global Hepatitis B Vaccines Sales Market Share Forecast by Application (2027-2032)
Figure 89. Global Hepatitis B Vaccines Revenue Market Share Forecast by Application (2027-2032)
More Publications
Global Duchenne Muscular Dystrophy Market Growth 2025-2031
US$ 3,660.00
January 2025
95 pages
Global Monosialyltetrahexose Ganglioside Sodium Injection Market Growth 2024-2030
US$ 3,660.00
August 2024
95 pages
Global High Content Analysis System Market Growth 2025-2031
US$ 3,660.00
May 2025
102 pages
Global Defibrillation Disposable Medical Electrodes Market Growth 2023-2029
US$ 3,660.00
March 2023
123 pages
Global Animal Infusion Pump Market Growth 2023-2029
US$ 3,660.00
March 2023
108 pages
